Tegaderm

Search documents
Solventum (SOLV) 2025 Conference Transcript
2025-05-13 22:20
Solventum (SOLV) 2025 Conference May 13, 2025 05:20 PM ET Speaker0 Next up, as you know, I'm Travis Steed, the BofA analyst at Bank of America. And next up, we have Solventum, Brian Henson, Chief Executive Officer, and Wade McMillan, Chief Financial Officer. So welcome, thank you. Speaker1 Yeah, thanks. Speaker0 Thanks for having us. Yeah, I just wanted to open it up. Think kind of a little over a year as a public company now. This is kind of your first conference a year ago. So just like maybe talk about s ...
143亿收入!医疗科技巨头最新财报
思宇MedTech· 2025-05-13 08:51
报名:首届全球心血管大会 | 最新议程 合作伙伴征集:2025全球手术机器人大会 2025年5月9日,新医疗科技巨头 舒万诺 Solventum (纽交所代码:SOLV) 公布了2025年第一季度财报表现。该季度销售额为 21亿美元 (约143亿元人民币),同 比增长 2.7% , 调整后的每股收益(EPS)为 1.34美元 ,均超出市场预期。 股价因此上涨 5% ,收于 70.02美元 。 自2024年4月从3M分拆以来, Solventum已迅速进入独立运营阶段,并在2025年第一季度交出了亮眼的财报。本文将深入分析舒万诺的财务表现、战略转型进展以 及面临的挑战和风险。 # 财务表现与未来展望 2025年第一季度, Solventum 在各大业务板块的表现强劲,具体财务数据如下: MedSurg(医疗外科) : 销售额为 12.81亿美元 (约61%),同比增长 3.4% ,主要得益于 V.A.C.负压伤口治疗系统 和 Tegaderm透明敷料 的市场需求。 Dental Solutions(牙科解决方案) : 销售额为 3.36亿美元 (约16%),同比增长 0.4% ,其中, SprintRay合作 ...
Solventum Corporation(SOLV) - 2025 Q1 - Earnings Call Presentation
2025-05-08 21:23
Q1 FY25 earnings presentation May 8, 2025 © Solventum 2025. All rights reserved. Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements ...